Dataset Viewer
Auto-converted to Parquet Duplicate
source_row_id
int64
17
446k
source_row_group
int64
0
2
source_row_in_group
int64
8
200k
source_dataset
stringclasses
1 value
source_revision
stringclasses
1 value
source_parquet_sha256
stringclasses
1 value
input_sha256
stringlengths
64
64
normalized_input_sha256
stringlengths
64
64
question_stem_sha256
stringlengths
64
64
contamination_index_sha256
stringclasses
1 value
domain
stringclasses
1 value
expected_answer
stringclasses
10 values
source_expected_answer
stringclasses
10 values
input
stringlengths
328
3.78k
output
stringlengths
1.07k
116k
verification
dict
98,971
0
98,971
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
48ca1674d2c237ef0ea199f42c67ea8c57deb5c57a06413c400b400e8edf7437
37c4ed7dcec4bf8e5d7efd4f67e2363043a1dba06daefc8c9f0f9b46f8ebde6b
5e3702c9375a31d53561b5c1336062bdcf35e268c3af1399002f1bdf085b2033
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
E
E
Solve the following problem. Make sure to put the answer (and only answer) inside \boxed{}. In a phase II trial of 16 patients with non-small cell lung cancer, response assessment per RECIST 1.1 showed the following outcomes after treatment: Patient 1: CR at week 8 and week 12 (confirmed CR). Patient 2: Baseline SLD 1...
<think> First, I need to calculate the investigator-assessed overall response rate (ORR) for this phase II trial with 16 patients. ORR is typically defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) as their best overall response, and it must be confirmed in most cases. ...
{ "domain_classifier": { "source_row_id": 98971, "domain_class": "TARGET_DOMAIN", "observed_domain": "oncology clinical trial response assessment", "confidence": "high", "rationale": "Requires RECIST-based oncology response classification and ORR calculation in NSCLC patients.", "classifier_ad...
17,529
0
17,529
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
9edf52751b013bfc3b06eb604dffc7ad22bfb1345c8b25ca0012d1ea7491b99d
0d5d48563dfb4d3f24475d7f02861e38612f4911fe4bd49ed42fef62864c1592
a1fae3bdf80267b9b1a8778a3f359d8c286a682ee0689217fff3f90045cc867c
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
C
C
Solve the following problem. Make sure to put the answer (and only answer) inside \boxed{}. A patient with a severe bacterial infection is prescribed Drug X intravenously. Drug X has a half-life of 8 hours, exhibits first-order kinetics, and has a narrow therapeutic index. It forms an active metabolite Y with a half-l...
<think> The problem involves calculating the maximum safe maintenance dose for Drug X with changing pharmacokinetics. Let me break it down. First, Drug X has a half-life of 8 hours and follows first-order kinetics. Its metabolite Y has a half-life of 24 hours. The therapeutic effect requires Drug X concentration above...
{ "domain_classifier": { "source_row_id": 17529, "domain_class": "TARGET_DOMAIN", "observed_domain": "clinical pharmacokinetics / dosing", "confidence": "high", "rationale": "Patient dosing for infection with therapeutic and toxicity constraints is clinical pharmacology.", "classifier_adapter_...
370,732
1
170,633
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
dfe2e2675fb52539ae84a81cd8433e69647d5e31e47017931cb082bbb3a8b0c9
a2dbcad0542b876d6bb34301df499eb87f0b24467b97f8867be28bddbf6f713f
53176d96b2bb379e9595a897598359cba696d242a0c1aeb5f9e64048aebe8cde
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
C
C
Solve the following problem. Make sure to put the answer (and only answer) inside \boxed{}. In a population, the prevalence of Disease X is 1%, and the prevalence of Disease Y is 2%. The presence of Disease X and Disease Y are not independent: if an individual has Disease X, the probability of having Disease Y is 50%....
<think> I need to find the probability that an individual actually has Disease X given that they tested positive for both diseases. The options are A: 84.5%, B: 86.5%, C: 87.0%, D: 89.1%. First, I am considering the given prevalences and dependencies. The prevalence of X is 1%, so P(X) = 0.01. Prevalence of Y is 2%, s...
{ "domain_classifier": { "source_row_id": 370732, "domain_class": "TARGET_DOMAIN", "observed_domain": "diagnostic testing / Bayesian clinical probability", "confidence": "high", "rationale": "Calculates posterior disease probability from test characteristics and comorbidity dependence.", "clas...
399,188
1
199,089
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
9ad31d7de0e0dc76794d252131c2d7b52a01d2dc93696865095f9ddbf6e62f94
cb8dbc7bbdd793048f48553c600baca89d200eb61d7d91833cadd06520a0cdb5
2fe87837dbbf206937c3dec4b4d6787d1459d9086caa1f5c4084d51a6fd7a5b6
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
B
B
Solve the following problem. Make sure to put the answer (and only answer) inside \boxed{}. In a clinical trial, a biomarker test is used to assign treatment. The true prevalence of the biomarker is 30%. The test has a sensitivity of 90% and a specificity of 80%. Patients with a positive test result receive Treatment ...
<think> I need to find the overall probability of a positive response in this clinical trial setup. The biomarker test has a sensitivity of 90% and specificity of 80%, with a true prevalence of 30%. Based on the test result, patients get Treatment A or B, and response rates depend on true biomarker status and treatment...
{ "domain_classifier": { "source_row_id": 399188, "domain_class": "TARGET_DOMAIN", "observed_domain": "biomarker-guided treatment probability", "confidence": "high", "rationale": "Clinical treatment assignment based on biomarker test performance and response rates.", "classifier_adapter_sha256...
329,921
1
129,822
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
8269fd38ea563834f925ac6ee16d93087d06ff578818f1ddca2664dc4836c3a5
66a18588cf43fcb4200c71b14843d9b31af3393fba3dee66357af57deaa2bb48
04af5abb9c15d170e5faef08498a070cc597d65947fba40a16914f53beaa1bec
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
D
D
"Solve the following problem. Make sure to put the answer (and only answer) inside \\boxed{}.\n\nCar(...TRUNCATED)
"<think>\nI need to solve this problem about CardioGuard, a prodrug metabolized by CYP2D6 and CYP3A4(...TRUNCATED)
{"domain_classifier":{"source_row_id":329921,"domain_class":"TARGET_DOMAIN","observed_domain":"pharm(...TRUNCATED)
100,175
0
100,175
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
3cbc327425f5862746e793fa4a66e002fed315563e1aa05f40ecc50c9ccedbb0
bcfca758f28de178b41bc368d3c0a0d880ec0cb91a69bcd319873e89d973bdd1
ab38a6085493026c95a7d430cd2ae4f2dc6503fa246856ec332d02c640c8a0f0
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
D
D
"Solve the following problem. Make sure to put the answer (and only answer) inside \\boxed{}.\n\nA p(...TRUNCATED)
"<think>\nWe are given a patient with severe hepatic impairment (Child-Pugh C) and hypoalbuminemia ((...TRUNCATED)
{"domain_classifier":{"source_row_id":100175,"domain_class":"TARGET_DOMAIN","observed_domain":"clini(...TRUNCATED)
38,641
0
38,641
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
1cac993538140b476e8213093342d3e6c21e6809daa77fdb7a667447453b05d9
d070c23fac36549c96be8d22dd4e1cfb01180a107f3d61d59ce231a54f6490e6
a9bcf84820c05c6f0b47d684f5838304de57ec6e6fcf5f1e2b234006fe43dc26
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
J
J
"Solve the following problem. Make sure to put the answer (and only answer) inside \\boxed{}.\n\nA p(...TRUNCATED)
"<think>\nFirst, the question is about a patient with oligometastatic HER2-positive breast cancer, s(...TRUNCATED)
{"domain_classifier":{"source_row_id":38641,"domain_class":"TARGET_DOMAIN","observed_domain":"multid(...TRUNCATED)
110,127
0
110,127
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
aae28ba967dd3f4279e00e5f579907a21193d2ef55eb36b380cb2a8862a6d4f2
4d8b170ac78bad1f409180d4e94f5d97f9142146180390cc42f260adc0ea0647
59d802718ea95e65b650e16803ff3f6faa891a84c57a35f9b6cff2c66b3df5a4
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
F
F
"Solve the following problem. Make sure to put the answer (and only answer) inside \\boxed{}.\n\nAcc(...TRUNCATED)
"<think>\nFirst, the question is about identifying which patient with documented atherosclerotic car(...TRUNCATED)
{"domain_classifier":{"source_row_id":110127,"domain_class":"TARGET_DOMAIN","observed_domain":"cardi(...TRUNCATED)
348,210
1
148,111
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
88c4bd6067e6a530b578b8098fbb4775eb185999acb5d541aeb1e3a819fdfe7e
32c70a92859b221ab567d5860ee3a842a8de17181bdce2344986ac25fbf8eb1a
c4850d3c6b28932ebe1efd26f2fcc251d56058eece51570a6df0d2cd81bcce51
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
B
B
"Solve the following problem. Make sure to put the answer (and only answer) inside \\boxed{}.\n\nA p(...TRUNCATED)
"<think>\nI need to figure out the therapeutic efficacy of Drug X for this patient compared to a ref(...TRUNCATED)
{"domain_classifier":{"source_row_id":348210,"domain_class":"TARGET_DOMAIN","observed_domain":"pharm(...TRUNCATED)
280,973
1
80,874
nvidia/OpenScienceReasoning-2
174b02c9cdf231f220765b2a1d5ece4550921894
e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
c793f11c34f5292b43a6c929ab52388c67ce4ab742d91dc0799af6faccb07313
92a5aa7c8661f2c128ab2a0ecd913387824e16c428d2af8e416736ed534b6ee0
50ebb3698dfeddff629c43d02f9571f93e94fb46bc3542f0897677c13f328546
92d260107f933e0d30ececc18292740a0b25f19492ab32fc14b903000ca97659
MEDICINE
B
B
"Solve the following problem. Make sure to put the answer (and only answer) inside \\boxed{}.\n\nRes(...TRUNCATED)
"<think>\nI need to determine for which patient the intervention of timed daily oral melatonin and b(...TRUNCATED)
{"domain_classifier":{"source_row_id":280973,"domain_class":"TARGET_DOMAIN","observed_domain":"sleep(...TRUNCATED)
End of preview. Expand in Data Studio

OpenSciReasoning-Medicine-20K

This is a 20,000-row Medicine subset derived from nvidia/OpenScienceReasoning-2 for domain-specific reasoner training and cross-domain transfer experiments.

Each record preserves the stable source_row_id, defined as the zero-based row index in the frozen source Parquet file.

Acceptance gates

  • High-confidence target-domain classification by the strict domain-only classifier.
  • Original source expected_answer retained.
  • Final answer parsed from the source reasoning trace matches the retained expected answer.
  • Unique source_row_id.
  • Unique normalized input.
  • Benchmark contamination check performed against the pinned local GPQA, SuperGPQA, and MMLU-Pro contamination index.
  • Source replay from the frozen OpenScienceReasoning-2 Parquet completed.

Provenance

  • Source dataset: nvidia/OpenScienceReasoning-2
  • Source revision: 174b02c9cdf231f220765b2a1d5ece4550921894
  • Source Parquet SHA-256: e82e9c7de7ac4befc12734d1b7b42b62c9896ba5bdef4e5d17cb7e7e8bceaef2
  • Data SHA-256: 91e557fed69704cef6255166b19c62473301ec7b3de05e8e99c9c3efffde80b4

Files

  • medicine_20000.jsonl: accepted training split, 20,000 rows.
  • audit/release_audit.json: final local audit.
  • audit/classification_collect_summary.json: classification collection summary, when available.

Automated filtering substantially improves data quality, but users should still perform task-specific validation before high-stakes use.

Downloads last month
33